Overview

Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized Phase II study to evaluate immunochemotherapy in patients with R0 OR R1-resected pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Carmen Schade-Brittinger
Treatments:
Cetuximab
Gemcitabine